Gabelli Funds LLC Grows Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Gabelli Funds LLC boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 130,350 shares of the medical equipment provider’s stock after buying an additional 14,400 shares during the period. Gabelli Funds LLC’s holdings in Zimmer Biomet were worth $11,721,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. North Dakota State Investment Board purchased a new stake in Zimmer Biomet during the 4th quarter valued at $611,000. United Bank raised its holdings in Zimmer Biomet by 8.2% during the 4th quarter. United Bank now owns 13,967 shares of the medical equipment provider’s stock valued at $1,256,000 after buying an additional 1,062 shares during the period. Canada Post Corp Registered Pension Plan raised its holdings in Zimmer Biomet by 40.0% during the 4th quarter. Canada Post Corp Registered Pension Plan now owns 3,673 shares of the medical equipment provider’s stock valued at $330,000 after buying an additional 1,050 shares during the period. Lawood & Co. bought a new position in Zimmer Biomet in the 4th quarter valued at $341,000. Finally, AlphaCore Capital LLC bought a new position in Zimmer Biomet in the 4th quarter valued at $793,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 1.2%

Shares of NYSE ZBH opened at $86.13 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The stock has a market capitalization of $16.66 billion, a P/E ratio of 22.37, a price-to-earnings-growth ratio of 1.97 and a beta of 0.48. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29. The business has a fifty day moving average price of $89.27 and a 200 day moving average price of $91.23.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is 24.94%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.28% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on ZBH. Citizens Jmp cut their price objective on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Truist Financial reaffirmed a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. BTIG Research reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a research report on Wednesday, April 29th. Finally, TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $102.80.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.